LSTM Home > LSTM Research > LSTM Online Archive

CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva

Anderson, Enyia, Patterson, Ian ORCID: https://orcid.org/0000-0003-3465-0848, Richards, Siobhan, PitolGarcia, Ana, Edwards, Thomas, Wooding, Dominic, Buist, Kate, Green, Alison, Mukherjee, Sayandip, Hoptroff, Michael and Hughes, Grant ORCID: https://orcid.org/0000-0002-7567-7185 (2022) 'CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva'. Journal of Medical Microbiology, Vol 71, Issue 2.

[img]
Preview
Text
jmm001508.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (821kB) | Preview

Abstract

Introduction. The importance of human saliva in aerosol-based transmission of SARS-CoV-2 is now widely recognized. However, little is known about the efficacy of virucidal mouthwash formulations against emergent SARS-CoV-2 variants of concern and in the presence of saliva.

Hypothesis. Mouthwashes containing virucidal actives will have similar inactivation effects against multiple SARS-CoV-2 variants of concern and will retain efficacy in the presence of human saliva.

Aim. To examine in vitro efficacy of mouthwash formulations to inactivate SARS-CoV-2 variants.

Methodology. Inactivation of SARS-CoV-2 variants by mouthwash formulations in the presence or absence of human saliva was assayed using ASTM International Standard E1052-20 methodology.

Results. Appropriately formulated mouthwashes containing 0.07 % cetylpyridinium chloride but not 0.2 % chlorhexidine completely inactivated SARS-CoV-2 (USA-WA1/2020, Alpha, Beta, Gamma, Delta) up to the limit of detection in suspension assays. Tests using USA-WA1/2020 indicates that efficacy is maintained in the presence of human saliva.

Conclusions. Together these data suggest cetylpyridinium chloride-based mouthwashes are effective at inactivating SARS-CoV-2 variants. This indicates potential to reduce viral load in the oral cavity and mitigate transmission via salivary aerosols.

Item Type: Article
Subjects: QW Microbiology and Immunology > Viruses > QW 160 Viruses (General). Virology
QY Clinical Pathology > Diagnostic Tests > QY 125 Saliva
WC Communicable Diseases > Virus Diseases > Viral Respiratory Tract Infections. Respirovirus Infections > WC 506 COVID-19
Faculty: Department: Biological Sciences > Vector Biology Department
Biological Sciences > Department of Tropical Disease Biology
Digital Object Identifer (DOI): https://doi.org/10.1099/jmm.0.001508
Depositing User: Samantha Sheldrake
Date Deposited: 28 Feb 2022 12:53
Last Modified: 28 Feb 2022 12:53
URI: https://archive.lstmed.ac.uk/id/eprint/19996

Statistics

View details

Actions (login required)

Edit Item Edit Item